We will test the efficacy and safety of a new antiviral drug, lobucavir, from Bristol Myers Squibb, in immunocompetent subjects with recurrent herpes labialis infections. Volunteers in this randomized, double-blind, placebo-controlled study will received one of two active doses of lobucavir or placebo twice daily for five days. Follow-up visits to the clinic will continue until the lesions are completely healed. Lobucavir has proven a potent antiviral in tissue culture and animal model studies. Therefore, the findings from these studies may help in developing a treatment that will hasten healing of lesions and reduce the severity or duration of the pain and discomfort associated with the infection.
Showing the most recent 10 out of 465 publications